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Abstract
Controlled human infection model (CHIM) studies have pivotal importance in
vaccine development, being useful for proof of concept, pathogenesis,
down-selection and immunogenicity studies.  To date, however, they have
seldom been carried out in low and middle income countries (LMIC), which is
where the greatest burden of vaccine preventable illness is found.  This
workshop discussed the benefits and barriers to CHIM studies in Malawi. 
Benefits include improved vaccine effectiveness and host country capacity
development in clinical, laboratory and governance domains.  Barriers include
acceptability, safety and regulatory issues. The report suggests a framework by
which ethical, laboratory, scientific and governance issues may be addressed
by investigators considering or planning CHIM in LMIC.
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Introduction
Controlled human infection models (CHIM), using ICH GCP 
guidelines1, have the potential to rapidly advance the development 
of vaccines with public health relevance to Africa. In a CHIM study, 
a well characterised strain of an infectious agent is administered 
at a controlled dose and by a specific route to carefully selected 
adult volunteers. Volunteers are closely monitored for evidence 
of carriage or infection under medical supervision to anticipate or 
manage symptoms of disease2.
Modern CHIM studies undergo detailed independent review and 
oversight, and therefore are entirely unrelated to the unaccept-
able and unregulated infectious challenges carried out in the past. 
This article relates only to well-regulated CHIM studies in the 
last 70 years, in which more than 22,000 people have volunteered. 
These studies have examined the pathogenesis, clinical features, 
microbiology, and the immune response to more than 15 pathogens 
of public health importance, as shown in Table 1. This has led to 
important discoveries in host-pathogen dynamics, and has been 
used to make drug development pathways more efficient and less 
costly.
To test host-pathogen interaction or vaccine targets in the 
country where the diseases occurs seems logical from ethical/ 
social point of view because the potential benefits of the results 
are in those countries3. But additionally, and equally very 
importantly, are the biological variables that might be impor-
tant in host-pathogen or host-vaccine interaction, which are very 
different in LMICs compared to, for example, the UK. Genetics, 
infectious disease history, co-infections, immune status, and 
environmental factors might likely play a role in how the host 
responds to the pathogen and/or the vaccine, and can only be 
appropriately tested in the targeted settings. That rationale 
actually requires the model to be run in the LMIC countries where 
the diseases occur.
To date, no CHIM studies have been carried out in Malawi4. 
This country has one of the lowest GDP in the world, with high 
Table 1. A selection of recent CHIM studies, time periods and degree of 
utilization (2015).
Challenge model Time periods of 
utilization
Number of 
challenge strains 
used so far
Approximate 
numbers of 
volunteers
Typhoid & 
Paratyphoid 
(enteric fevers)
1952–1974; 
2012–present
2 2,200
Influenza 1976–present 4 1,500
Malaria 1986–present 4 1,000
Pneumococcal 
carriage
2000–2005; 
2012–present
2 850
Shigella 1946–1995; 
2006–present
9 750
Enterotoxigenic 
Escherichia coli
1971–1999; 
2007–present
11 500
Neisseria 
lactamica
1 398
Campylobacter 1988–1998; 
2009–present
5 225
Norovirus 1990–2005; 
2012–present
3 220
Cholera 1983–2005; 
2010–present
3 200
Cryptosporidium 1995–2006; 
2014–present
5 110
Respiratory 
Syncytial Virus 
(RSV)
1985–2000; 
2010–present
2 150
Dengue 1945–1952; 
2010–present
7 50
Mycobacteria 
(BCG)
2012–present 1 40
References for many of these studies are included in the comprehensive review by Darton 
(2015)5.
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Table 2. Issues highlighted for any potential CHIM studies in Malawi.
Potential benefits Challenges
Accelerating or streamlining vaccines/treatment relevant to 
the national health burden. 
 
Building local capacity in: clinical facilities; laboratory 
diagnostics; experimental medicine; clinical governance; and 
regulatory confidence. 
 
Opportunity to construct Malawi’s regulatory framework to 
suit its own needs rather than adopting one from the EU/US. 
 
Improving science capacity through work-based training and 
mentorship of local scientists. 
 
Understanding key scientific questions relevant to public 
health in Malawi, including the effect of genetics, endemic 
infectious disease and co-infections, immune status, and 
environmental factors. These unique combinations of effects 
cannot be correctly understood in a model run elsewhere.
Current infrastructure and clinical facilities may not be 
ready for CHIM (specifically, monitoring and supporting 
adverse events e.g. on intensive care units). 
 
Inherent vulnerabilities may hamper fully informed consent 
in the local context (languages, assessment understanding, 
participant criteria suitability, cultural family/group consenting). 
 
Poor community hygiene and sanitation infrastructure 
could prevent effective control measures (e.g. typhoid in 
out-patient settings). 
 
Production of challenge stain locally may have QA issues, 
but “international” strains may be less relevant - resulting 
long supply chains need careful management.  
 
Consensus on appropriate compensation for monetary 
and opportunity costs is lacking: the balance between 
appropriate recompense and incentivisation is difficult and 
locally variable. 
 
Malawi has not yet hosted Phase 1 studies, or those 
including healthy volunteers who are expected to become 
symptomatic due to the research protocol; there is a relative 
shortage of skills and experience
burdens of morbidity and mortality from infectious disease. 
The reasons why CHIM studies are not carried out in Low and 
Middle Income Countries (LMIC) include technical, clinical, 
ethical and regulatory issues, as well as cultural norms. The 
cost-benefit analysis of CHIM studies might, however, show 
substantial benefit to LMIC, as an expedient approach to major 
infectious challenges in a resource poor setting. A workshop was 
convened to discuss the scientific and public health value of con-
ducting CHIM studies in Malawi, and the research governance 
issues that need to be addressed. There was a plurality of views 
from workshop participants, specifically around the readiness of 
scientific and clinical stakeholders in Malawi, and the advisabil-
ity of challenge model implementation. These are recognised in 
Table 2, with key challenges highlighted below. Where these are 
addressed, we propose a possible roadmap for undertaking CHIM 
in Malawi.
CHIM design issues
Considerations in the design, recruitment, and microbiology of 
CHIM studies have been recently reviewed5. CHIM studies provide 
the opportunity to study many aspects of the course of a micro-
bial infection, along with assessing the response to treatment and 
the efficacy of naturally acquired and vaccine induced immune 
responses. They provide an efficient framework for selecting 
vaccine and drug candidates for further development and can be 
carried out on a much smaller number of volunteers, and much 
more rapidly than Phase IIb-III studies. Protection against 
specific microbial strains can be evaluated in a controlled set-
ting, and biomarkers to resistance and protection against infection 
can be efficiently assessed. Therefore, CHIM studies can acceler-
ate vaccine development and evaluation.
CHIM studies require safe and accurate microbiology, good 
clinical facilities, careful recruitment and monitoring and close 
governance. Models are limited to those pathogens that are both 
detectable and treatable or self-limiting; complete clearance is 
usually required before the end of the study. Attenuated strains 
are sometimes used, to minimize potential symptoms and risks, or 
to assess the challenge agent itself as a vaccine candidate.
Current CHIM models in LMIC
CHIM have been developed for many diseases where the glo-
bal burden is predominantly borne by LMIC, but few have been 
carried out among the populations of these countries. Malaria 
infection models have a very long history in Africa6, and has 
recently been revived in Kenya7, Tanzania8 and Gabon9. A Shigella 
sonnei CHIM study in Thailand, as well as a cholera study, were the 
first enteric infection CHIM studies in LMIC10.
Reasons to consider further CHIM in LMIC
Vaccine trial results have been highly variable in different 
global regions, and sometimes promising results from high income 
settings have not been replicated in LMIC. There are good rea-
sons to expect that, compared with high income countries, there 
are different host-pathogen relationships in LMIC for vector-
borne diseases (malaria and dengue), enteric diseases (cholera, 
enterotoxigenic Escherichia coli [ETEC], Shigella, Campy-
lobacter, typhoid fevers and norovirus), and some respiratory 
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pathogens (influenza, RSV, pneumococcus, Neisseria and non-
tuberculous mycobacteria). These differences in disease epi-
demiology are a result of multiple factors, including naturally 
acquired immunity, dietary factors, intestinal microbiota, and 
the genetic profile of the host population.
New vaccines against several of the diseases for which CHIM 
have been developed, are either licensed or in intermediate or 
advanced stages of development. These diseases include malaria, 
cholera, ETEC, Shigella, typhoid, influenza, pneumococcal 
pneumonia and TB. There is, however, no affordable and achiev-
able path to licensure for most of these candidate vaccines and 
no means of choosing between the vaccine candidates based on 
the immunological response of vaccinated individuals in exposed 
population.
CHIM have played a pivotal role in the development of vaccines 
against enteric diseases including the cholera vaccine Dukoral® 
and typhoid vaccine Ty21a (Vivotif®)11,12. Additionally, in 2016, a 
live, oral, cholera vaccine (Vaxchora®) was the first vaccine where 
CHIM provided the primary evidence of effectiveness required 
for licensure by the FDA for use in the US. The path to licen-
sure for new malaria and typhoid vaccines now includes CHIM at 
Phase 2a13. The development of current malaria vaccine RTS,S 
(GSK) was facilitated by CHIM14.
In the case of pneumococcal vaccine development, carriage is a 
tenable surrogate endpoint in the testing of new vaccines, as the 
number of subjects required for a clinical Phase 3 study includ-
ing current conjugate vaccine in the control arm exceeds 200,000 
individuals. CHIM studies are typically much smaller, requiring 
fewer than 150 subjects, using carriage as an endpoint15. These 
may provide data to discontinue development of under-performing 
vaccine candidates, particularly when combined with infant natural 
carriage studies, and enable the identification of a vaccine to take 
forward.
Scientific reasons to consider further CHIM in LMIC therefore 
include: the need to focus testing of late stage novel vaccines; the 
record of CHIM success in enteric vaccine and malaria vaccine 
development; the potential for accelerated development of as yet 
undiscovered vaccines.
Considerations in designing CHIM studies specific to 
LMIC
As CHIM studies involve the deliberate infection of healthy 
volunteers with infectious agents, these studies are technically 
challenging, and require careful ethical consideration of both 
risk to participants, and to their contacts, and the provision of 
robust clinical service to support the participant should an adverse 
event occur. These key issues of acceptable levels of risk and 
adequately informed consent are paramount in any global 
region5, with specific issues which make LMIC more vulner-
able. As an overarching principle, CHIM studies in LMIC should 
be designed with a “equivalent international” standard, in which 
the study is conducted at least as well as it could have been done 
anywhere in the world, exemplified by leading LMIC work on 
malaria studies7.
Clinical facility & healthcare provision considerations
Clinical facilities to recruit and manage study participants in LMIC 
must ensure that the infection risk is no greater than elsewhere 
in the world. This consideration must extend to include not only 
the clinical rooms, but also referral pathways, transport, diag-
nostic investigation and treatment. The design and development 
of CHIM studies in LMIC under the equivalent international 
standard may provide an opportunity to improve clinical services 
in resource-poor settings.
The decision to adopt inpatient or outpatient design, including 
consideration of isolation, must be made based on the pathogen- 
associated risk in the local context. Clinical assessment will 
typically be used at screening to identify healthy participants 
at minimal risk of incidental illness during the CHIM. Inclusion 
and exclusion criteria for participants in endemic settings may 
include recent and past infection, determined by available medical 
records and immunological screening. Further, in endemic settings, 
consideration of circulating vectors (e.g. malaria), community 
prevalence of carriage (e.g. pneumococcal carriage) and the level 
of community hygiene and sanitation infrastructure (e.g. typhoid) 
to ensure community safety are required.
Technical considerations
Challenge strain – the choice and availability of a pathogen strain 
is a crucial methodological consideration. Quality Assurance (QA) 
of inocula is key, from manufacture (which may require Good 
Manufacturing Practice certification) through to a regulated 
delivery pathway to the volunteer. In the LMIC context, QA 
considerations from production to administration are a particular 
logistic challenge. While imported stock will have a long supply 
line, a centrally manufactured product will maximise comparabil-
ity between sites. For locally generated stock, GMP production 
standards may be more challenging, but strict QA procedures are 
required at the study site whichever route is taken.
Endpoints – Endpoints for CHIM studies must be consistently 
defined, and easily identified before the onset of any significant 
pathology, in order to minimise the risk to participants, and to 
ensure that clinical or scientific outcomes are assessed. Endpoints 
vary across models, but can be dependent on the diagnosis of infec-
tion, the development of infection symptoms, or the assessment of 
infection severity. Using endpoints of the development of infec-
tion provides a unique opportunity to identify and validate novel 
biomarkers and diagnostic tests. In the LMIC context, CHIM end-
point diagnosis could provide valuable capacity building within 
local laboratory services.
Community perception and engagement
Community perceptions vary widely around the world with respect 
to the understanding of infection risk, disease severity, treatment 
availability and effectiveness and vaccination to prevent disease7. 
The underlying anxieties are likely to be similar in many regions, 
but the means to address them should be locally determined in 
LMIC in advance of study design, using regionally appropriate 
programmes of community engagement, consultation and educa-
tion. It is recommended that CHIM studies are based on a deep 
understanding of the local community’s perceptions based on prior 
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experience and previous engagement, and from a position of estab-
lished mutual trust.
Ethical considerations
Volunteer recruitment, advertising and the means to ensure that 
consent is fully informed will vary in different regions16. The 
international standards for consent do not vary, but the means 
of information provision and of gaining a response are different 
in many LMIC. Proper methods must be developed by consulta-
tion with communities and with locally experienced researchers. 
Concepts of infection and disease may vary widely as may the 
extent of individual autonomy in providing consent. Advertising 
and remuneration are also different between regions and appro-
priate stakeholder consultation should determine the balance 
between incentivised research (too much perceived benefit) and 
lack of appropriate compensation for the negative impact on earn-
ings and opportunity cost for participants (too little remunera-
tion). A full study of these considerations has been reported from 
Kenya7. Research Ethics Committees (RECs) have developed 
regulatory and ethical review and oversight experience with 
CHIM studies over time. At an early stage of development, 
local RECs should be encouraged to develop relationships with 
CHIM-experienced RECs to seek advice and share experiences. 
Training materials could be developed by collaboration between 
research sites and groups.
Legal and regulatory considerations
CHIM studies have a more complex regulatory requirement in the 
US than the European Union (including the UK). In the US, but not 
in the EU, challenge and re-challenge studies that do not include a 
vaccine are subject to review at the national level. Further, in the 
US, the challenge strains themselves are usually required to meet 
a level of compliance with GMP, similar to that required for vac-
cines entering Phase 1 clinical trials. In the EU/UK, this condition 
is commonly not required, as summarised in Table 3, although 
QA/QC procedures following GMP principles should be in place. 
In the UK, there are few guidelines for setting up new CHIM 
studies and a more structured pathway would be useful.
Regulatory authorities in addition to RECs include medicines 
regulatory boards (e.g. Medicines and Healthcare products 
Regulatory Agency (MHRA, UK), European Medicines Agency 
(EMA); Food and Drug Administration (FDA, USA), Pharmacy, 
Medicines and Poisons Board (PMPB, Malawi). Legal posi-
tions vary substantially and may include the Departments of 
Agriculture and Environment. In the USA challenge agents are 
classed as pharmacologically active agents, and the FDA must 
approve their release. In contrast, in the UK challenge agents are 
not classed as pharmaceutical products and regulatory approv-
als from the MHRA are not required before CHIM experiments. 
In both the US and EU, CHIM studies that incorporate testing of 
an Investigational Medicinal Product (IMP) require the relevant 
medicines agency approval. The Kenyan regulatory process is 
managed by a REC, Pharmacy and Poisons Board, and local 
research governance processes.
Sponsorship, governance and compensation
CHIM studies in LMIC have strong collaborative links with the 
research institution in which the CHIM was initially developed, 
although may be led from research institutions in the country. 
Sponsorship has been undertaken by the original institution, or 
in the case of IMPs, by the commercial entity responsible for 
developing the IMP to market. Data Monitoring and Safety Boards 
are recommended for all CHIM studies. These boards should be 
Table 3. Types of controlled human challenge studies and their regulatory requirements.
Study type and description Regulatory requirements in the US Regulatory requirements in the UK
Challenge study: A challenge strain 
of a pathogen is administered to 
healthy adult volunteers.
Study must be conducted under an 
Investigational New Drug (IND) application 
that has been approved by the US Food and 
Drug Administration. Challenge strains are 
ideally manufactured in compliance with GMP 
at a level similar to that required for a product 
to be studied in a Phase 1 clinical trial. Once 
approved, INDs (or master drug files) for 
challenge strains may be cross-referenced in 
subsequent studies. In addition, the study must 
undergo review and approval by an IRB, or 
multiple IRBs if the study is to be conducted at 
multiple sites. Other review agencies may also 
have jurisdiction under certain circumstances 
(see Table 2).
Study does not require review by the 
MHRA if it does not involve a vaccine 
or other IMP. The challenge strains 
do not necessarily need to meet GMP 
requirements. Review and approval by 
an IRB is a requirement, and by other 
agencies in select circumstances (see 
Table 2).
Re-challenge study: A challenge 
strain of a pathogen is administered 
to healthy adult volunteers 
previously challenged with the same 
strain or a heterologous strain.
Vaccine trial using a challenge 
model: A candidate vaccine is 
administered to healthy adult 
volunteers, who are later (or in some 
cases, previously) challenged with 
one or more strains of the pathogen 
against which the vaccine or drug is 
directed.
Candidate vaccine must be administered 
under an approved IND application and must 
undergo ethical review and approval by the 
relevant IRB(s), in addition to the approvals for 
the challenge strain and study procedures as 
described above. 
Candidate vaccine must be 
administered under an MHRA approved 
application. The protocol must also 
undergo ethical review and approval by 
the relevant IRB(s).
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small, and include statistics, ethics, technical and clinical advisors 
that are immediately responsive to the study team and sponsor. 
Insurance requirements vary by country, but no-fault compensation 
would normally be preferred as for any clinical trial.
Genetically modified organisms
Using strains that have been genetically modified or attenuated 
requires additional approvals in most regions (the release of ‘genet-
ically modified’ organisms [GMO]). Strain libraries and large-
scale production of standardised pre-frozen strains may make the 
regulation of GMO more straightforward as data obtained in each 
study site will inform other experiments. GMO-related regulatory 
requirements vary by country, but are often regulated by the Minis-
try of Agriculture (such as DEFRA in UK).
Summary: A possible roadmap for CHIM studies in 
Malawi
Consider the need, benefit, science, ethics and model 
quality
In relation to CHIM studies in Malawi, the first consideration 
should be whether the burden of disease being studied is of suf-
ficient importance to justify the risks associated with participant 
involvement, and the costs, including opportunity costs, of the 
effort. This is most easily judged by the degree of alignment with 
the National Research Agenda: in a resource constrained setting, 
there is little justification for research outside the national strategy.
The second consideration is whether the scientific and ethical case 
to justify the work has been met. In the LMIC context, the science 
may differ as a result of endemic exposure to pathogen, vector and 
co-infections. The ethical issues are similar in high and low income 
settings, but have local contextual nuance as well as the “equivalent 
international standard” principle. Inoculum preparation, dose and 
delivery considerations will vary by pathogen, study and site.
Third, we consider that an important factor is whether intro-
duction of the model would substantially increase the national 
capacity in clinical facilities, laboratory diagnostics, experimen-
tal medicine, clinical governance and regulatory confidence. The 
capacity building element is a major ethical consideration in 
the LMIC context, particularly if CHIM studies can materially 
improve the government health services.
Fourth, it is understood that, at this time, CHIM models should 
be developed in maximally resourced settings before introduction 
to LMIC. Before transition to LMIC, several studies should have 
arisen, from which the quality of the CHIM might be assessed. This 
set of considerations is laid out in Figure 1.
Regulatory considerations
The WHO Expert Committee on Biological Standardization, 2016, 
‘Human Challenge Trials for Vaccine Development: regulatory 
considerations’17 recognised that regulation of CHIM trials need 
to be well defined by the national regulatory authorities and vac-
cine developers, and manufacturers need to be aware of regulatory 
expectations.
Figure 1. A framework for consideration of CHIM in Malawi.
In Malawi, the National Commission for Science and Technol-
ogy (NCST) appoints the National Health Sciences Research 
Committee (NHSRC) to review the application to conduct any 
CHIM studies, as this type of research falls under the category 
of “national interest”. The PMPB is the drug regulatory authority 
that approves the use of drugs and vaccines. These authorities are 
the appropriate bodies to regulate CHIM. At this time, there is an 
opportunity for Malawi to define its own regulatory pathway for 
CHIM work.
Conclusion
The workshop concluded that CHIM studies should be considered 
in Malawi if the studies addressed public health challenges and 
needs on the National Research Agenda, ensured capacity develop-
ment, and had appropriate scientific and ethical rigour. This rigour 
would include the considerations of benefit and risk described for 
any CHIM, together with the local LMIC considerations laid out in 
this workshop report.
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Medicine, University of Malawi), Joe Mfutso Bengo (College of 
Medicine, University of Malawi), Kamija Phiri (College of Medi-
cine, University of Malawi), Kate Gooding (Malawi-Liverpool 
Wellcome Trust), Kondwani Jambo (Malawi-Liverpool 
Wellcome Trust), Leo Masamba (Queen Elizabeth Central Hospital 
(QECH), Ministry of Health), Louisa Alfazema (College of Medi-
cine, University of Malawi), Lucinda Manda Taylor (College of 
Medicine, University of Malawi), Marcus Gmeiner (Malawi-
Liverpool Wellcome Trust), Melissa Kapulu (KEMRI Wellcome 
Trust), Melita Gordon (Malawi-Liverpool Wellcome Trust), Mike 
Kachedwa (National Commission for Science and Technology), 
Mphatso Kawaye (Pharmacy, Medicines and Poisons Board), Peter 
Finch (College of Medicine, University of Malawi), and Victor 
Mwapasa (College of Medicine, University of Malawi).
The international attendees were: Amy Luck (The Wellcome 
Trust), Anastazia Older Aguilar (Bill and Melinda Gates Founda-
tion), Charles Sande (KEMRI Wellcome Trust), Daniela Ferreira 
(Liverpool School of Tropical Medicine), Debby Bogaert (Univer-
sity of Edinburgh), Jamie Rylance (Liverpool School of Tropical 
Medicine), Malick Gibani (University of Oxford), Meta Roestenberg 
(Leiden University Medical Centre), Narcis Kabatereine (Uganda 
Ministry of Health), Patricia Njuguna (KEMRI Wellcome 
Trust), Philip Bejon (KEMRI Wellcome Trust), Rob Heyderman 
(University College London), Rob Read (University of Southampton), 
Winfred Naziwa (Uganda National Council for Science and 
Technology).
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This is generally a well-crafted synopsis of the regulatory, logistical, ethical and community issues facing
the performance of CHIM research in LMIC. Some minor points for consideration.
The author state “Clinical facilities to recruit and manage study participants in LMIC must ensure
.” Rephrase for greater clarity- is thisthat the infection risk is no greater than elsewhere in the world
a reference to risks faced by participants or risks posed to community contacts/environment?
 
Challenge strain and method of production–  most LMIC will not be able to manufacture GMP
stocks of challenge pathogen– we are then left with a loose framework (i.e. the UK scenario) for
“home-made” brews of challenge strain production that accepts a pragmatic but lower level of
scrutiny on production and testing. Should the authors be more forceful in motivating the scientific
and regulatory community for guidance on this issue? i.e. what are the minimum requirements for
production and testing?
 
Where relevant, insert a sentence or two to expand upon the differences between human infection
models     models.versus disease
 
The authors rightly point to the importance of deep and wide community engagement before and
during CHIM establishment. It might be useful to describe how “acceptance” could be measured
before during after CHIM research. e.g. via discussions with community reference groups and/or
civil society actors.
 
Table 3. Could include mention of other applications of CHIM, e.g. prophylaxis or therapeutic
studies of novel drug candidates.
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Many thanks for these insightful remarks and questions.  The next steps in Malawi (before any
proposal to proceed to CHIM study) are to form study groups to determine:
a) the conditions for clinical safety - including both the volunteers, staff and other community
contacts.
b) the laboratory conditions for accurate, safe preparation of challenge inocula. This discussion will
include import & regulate or local production methods.
c) the means to determine acceptability and the degree of acceptability of this work
Certainly we will produce further documents when these groups have reported. 
 Prof Simmons has been recently appointed as a member of the MLWCompeting Interests:
Independent Scientific Advisory Board and as such will have the opportunity to directly evaluate
and review progress when he visits Malawi in due course.
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This is a clear description of the workshop on controlled human infection model (CHIM) in Malawi. As
such there is no new data or experimental details to analyse / review and the article is scientifically sound,
covering the background and available literature on CHIM studies in the discussion. Due to the paucity of
CHIM studies in low / middle income countries (LMIC) it would have been good to have had a more in
depth review of these studies in higher income countries, particularly those that are more relevant to LMIC
conditions e.g. the malaria and typhoid challenge studies. The figures and tables are clear and the road
map discussion is a good guide to the challenges in developing these studies (a comment in this section
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 map discussion is a good guide to the challenges in developing these studies (a comment in this section
on volunteer recruitment and remuneration in LMIC as opposed to higher income would have been
interesting).
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Many thanks for these comments. 
CHIM studies have been comprehensively reviewed by Darton and colleagues (Lancet Infect Dis
2015;15(7):840-51) and so this paper aimed to draw attention to the potential utility and pathway to
implementation for CHIM in LMIC.
Remuneration strategy will form part of the consultation process to be carried out next in Malawi. 
The experience in experimental studies (e.g. research bronchoscopy) and from multiple
discussions with REC both in LMIC and in high income settings is that full consultation with the
entire study team is the best way to guide a decision about remuneration. 
 Dr Gordon and Dr Lillie both serve on a recently formed CHIM DSMBCompeting Interests:
serving a UK study.
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